Investigating survival rates in patients with advanced liver cancer
The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region
This study looks at how long people with advanced liver cancer who can't have surgery are living and what treatments they are getting in real-life situations across Asia Pacific.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Humanity & Health Medical Group Limited Academic / other |
| Locations | 3 sites (Beijing and 2 other locations) |
| Trial ID | NCT03612726 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the overall survival of patients diagnosed with unresectable hepatocellular carcinoma (HCC) in real-world settings across the Asia Pacific region. By focusing on patients who cannot undergo surgical resection, the study seeks to gather data that reflects the actual outcomes and treatment patterns in this population. The research will involve collaboration with prominent institutions in China and Japan to ensure a comprehensive understanding of HCC's impact in these regions.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with unresectable hepatocellular carcinoma who can provide informed consent.
Not a fit: Patients who are willing to participate but do not have a diagnosis of unresectable hepatocellular carcinoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into survival outcomes for patients with unresectable HCC, potentially guiding future treatment strategies.
How similar studies have performed: While there have been studies on HCC, this specific observational approach focusing on real-world survival outcomes in unresectable cases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a diagnosis of unresectable hepatocellular carcinoma * Able to comprehend and provide written informed consent in accordance with institutional guidelines. Exclusion Criteria: * Patients not willing to participate and/or give their written informed consent.
Where this trial is running
Beijing and 2 other locations
- Beijing 302 Hospital — Beijing, China (Recruiting)
- Humanity & Health Medical Group Limited — Hong Kong, Hong Kong (Recruiting)
- Tokyo University — Tokyo, Japan (Recruiting)
Study contacts
- Study coordinator: Danny Wang, PhD
- Email: danny.wang@hnhmgl.com
- Phone: +852-21160598
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.